Abstract:AbstractNasopharyngeal carcinoma (NPC) is prevalent in Southern China and Southeast Asia, and autoantibody signatures may improve early detection of NPC. In this study, serum levels of autoantibodies against a panel of six tumor-associated antigens (p53, NY-ESO-1, MMP-7, Hsp70, Prx VI, and Bmi-1) and Epstein–Barr virus capsid antigen-IgA (VCA-IgA) were tested by enzyme-linked immunosorbent assay in a training set (220 NPC patients and 150 controls) and validated in a validation set (90 NPC patients and 68 controls). We used receiver-operating characteristics (ROC) to calculate diagnostic accuracy. ROC curves showed that use of these 6 autoantibody assays provided an area under curve (AUC) of 0.855 [95% confidence interval (CI), 0.818–0.892], 68.2% sensitivity, and 90.0% specificity in the training set and an AUC of 0.873 (95% CI, 0.821–0.925), 62.2% sensitivity, and 91.2% specificity in the validation set. Moreover, the autoantibody panel maintained diagnostic accuracy for VCA-IgA–negative NPC patients [0.854 (0.809–0.899), 67.8%, and 90.0% in the training set; 0.879 (0.815–0.942), 67.4%, and 91.2% in the validation set]. Importantly, combination of the autoantibody panel and VCA-IgA improved diagnostic accuracy for NPC versus controls compared with the autoantibody panel alone [0.911 (0.881–0.940), 81.4%, and 90.0% in the training set; 0.919 (0.878–0.959), 78.9%, and 91.2% in the validation set), as well as for early-stage NPC (0.944 (0.894–0.994), 87.9%, and 94.0% in the training set; 0.922 (0.808–1.000), 80.0%, and 92.6% in the validation set]. These results reveal autoantibody signatures in an optimized panel that could improve the identification of VCA-IgA–negative NPC patients, may aid screening and diagnosis of NPC, especially when combined with VCA-IgA. Cancer Prev Res; 8(8); 729–36. ©2015 AACR.

Advances of Biomarkers in Nasopharyngeal Carcinoma's Early Detection.

[Detection of EBV-LMP1 antibodies in sera and clinical significance in the patients with nasopharyngeal carcinoma].

Recent Advances in the Development of Biomarkers and Chemoradiotherapeutic Approaches for Nasopharyngeal Carcinoma.

Current Status and Future Perspectives about Molecular Biomarkers of Nasopharyngeal Carcinoma

Progress of tumor marker research in Nasopharyngeal carcinoma

Molecular Diagnosis of Nasopharyngeal Carcinoma: Past and Future

Systematic comparison of plasma EBV DNA, anti-EBV antibodies and miRNA levels for early detection and prognosis of nasopharyngeal carcinoma

Biomarker Discovery of Nasopharyngeal Carcinoma by Proteomics

Advances in Pathogenesis and Precision Medicine for Nasopharyngeal Carcinoma

Recent advances in early detection of nasopharyngeal carcinoma

Quantification of Epstein-Barr Virus DNA Load in Nasopharyngeal Brushing Samples in the Diagnosis of Nasopharyngeal Carcinoma in Southern China.

Research status and prospects of biomarkers for nasopharyngeal carcinoma in the era of high-throughput omics (Review)

Extensive Serum Biomarker Analysis in Patients with Nasopharyngeal Carcinoma.

Evaluation of Circulating EBV Microrna BART2‐5p in Facilitating Early Detection and Screening of Nasopharyngeal Carcinoma

Autoantibody Signatures Combined with Epstein-Barr Virus Capsid Antigen-Iga As A Biomarker Panel for the Detection of Nasopharyngeal Carcinoma

The Prevalence and Prevention of Nasopharyngeal Carcinoma in China

Serological profiling using an Epstein-Barr virus mammalian expression library identifies EBNA1 IgA as a pre-diagnostic marker for nasopharyngeal carcinoma

Serologic Profiling Using an Epstein-Barr Virus Mammalian Expression Library Identifies EBNA1 IgA As a Prediagnostic Marker for Nasopharyngeal Carcinoma

Early Stage and Locally Advanced Nasopharyngeal Carcinoma Treatment from Present to Future: Where Are We and Where Are We Going?

Recent Advances in Assessing the Clinical Implications of Epstein-Barr Virus Infection and Their Application to the Diagnosis and Treatment of Nasopharyngeal Carcinoma

Autoantibodies As Potential Biomarkers of Nasopharyngeal Carcinoma (NPC)